Franã§ois Guã©rard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2296255/publications.pdf

Version: 2024-02-01

28 papers 856 citations

430874 18 h-index 24 g-index

30 all docs 30 docs citations

times ranked

30

1142 citing authors

#	Article	IF	CITATIONS
1	Radiolabeling chemistry with heavy halogens iodine and astatine. , 2022, , 121-132.		1
2	How radiolysis impacts astatine speciation?. Radiation Physics and Chemistry, 2022, 198, 110224.	2.8	0
3	Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies. Chemical Science, 2021, 12, 1458-1468.	7.4	18
4	Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight― Pharmaceutics, 2021, 13, 906.	4.5	69
5	Advances in the Chemistry of Astatine and Implications for the Development of Radiopharmaceuticals. Accounts of Chemical Research, 2021, 54, 3264-3275.	15.6	30
6	211 At and 125 I‣abeling of (Hetero)Aryliodonium Ylides: Astatine Wins Again. Chemistry - A European Journal, 2021, , .	3.3	5
7	Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in a Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease. Cancers, 2020, 12, 2721.	3.7	11
8	Reply to the â€~Comment on "Investigation of Zr(iv) and 89Zr(iv) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imagingâ€â€™ by A. Bianchi and M. Savastano, Chem. Commun., 2020, 56, D0CC01189D. Chemical Communications, 2020, 56, 12667-12668.	4.1	2
9	Cell Tracking in Cancer Immunotherapy. Frontiers in Medicine, 2020, 7, 34.	2.6	52
10	Radioimmunotherapy of Lymphomas. , 2019, , 113-121.		3
10	Radioimmunotherapy of Lymphomas. , 2019, , 113-121. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. International Journal of Molecular Sciences, 2019, 20, 2564.	4.1	22
	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. International Journal of	4.1	
11	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. International Journal of Molecular Sciences, 2019, 20, 2564. Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies. Bioorganic and Medicinal Chemistry, 2019, 27,		22
11 12	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. International Journal of Molecular Sciences, 2019, 20, 2564. Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies. Bioorganic and Medicinal Chemistry, 2019, 27, 167-174. Prospects for Enhancing Efficacy of Radioimmunotherapy. Resistance To Targeted Anti-cancer	3.0	22
11 12 13	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. International Journal of Molecular Sciences, 2019, 20, 2564. Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies. Bioorganic and Medicinal Chemistry, 2019, 27, 167-174. Prospects for Enhancing Efficacy of Radioimmunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 139-153. Investigation of the complexation of ^{nat} Zr(<scp>iv</scp>) and ^{Sg} Zr(<scp>iv</scp>) by hydroxypyridinones for the development of chelators for PET	3.0	22 25 1
11 12 13	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. International Journal of Molecular Sciences, 2019, 20, 2564. Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies. Bioorganic and Medicinal Chemistry, 2019, 27, 167-174. Prospects for Enhancing Efficacy of Radioimmunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 139-153. Investigation of the complexation of ^{nat} Zr(<scp>iv</scp>) and ^{Zr(<scp>iv</scp>) by hydroxypyridinones for the development of chelators for PET imaging applications. Dalton Transactions, 2017, 46, 4749-4758. Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert}	3.0 0.1 3.3	22 25 1 26
11 12 13 14	What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr- and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model. International Journal of Molecular Sciences, 2019, 20, 2564. Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies. Bioorganic and Medicinal Chemistry, 2019, 27, 167-174. Prospects for Enhancing Efficacy of Radioimmunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 139-153. Investigation of the complexation of ^{nat} Zr(<scp>iv</scp>) and ^{S9} Zr(<scp>iv</scp>) by hydroxypyridinones for the development of chelators for PET imaging applications. Dalton Transactions, 2017, 46, 4749-4758. Radioimmunoconjugates for treating cancer: recent advances and current opportunities. Expert Opinion on Biological Therapy, 2017, 17, 813-819. Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies.	3.0 0.1 3.3 3.1	22 25 1 26 27

#	Article	IF	CITATIONS
19	Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts. Chemistry - A European Journal, 2016, 22, 12332-12339.	3.3	33
20	Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts. Chemistry - A European Journal, 2016, 22, 12205-12205.	3.3	0
21	Radioimmunotherapy for Treatment of Acute Leukemia. Seminars in Nuclear Medicine, 2016, 46, 135-146.	4.6	31
22	Tumor Immunotargeting Using Innovative Radionuclides. International Journal of Molecular Sciences, 2015, 16, 3932-3954.	4.1	51
23	Rational Design, Synthesis, and Evaluation of Tetrahydroxamic Acid Chelators for Stable Complexation of Zirconium(IV). Chemistry - A European Journal, 2014, 20, 5584-5591.	3.3	63
24	Radioiodinated and astatinated NHC rhodium complexes: Synthesis. Nuclear Medicine and Biology, 2014, 41, e23-e29.	0.6	10
25	Investigation of Zr(<scp>iv</scp>) and ⁸⁹ Zr(<scp>iv</scp>) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chemical Communications, 2013, 49, 1002-1004.	4.1	99
26	Production of [$<$ sup $>211sup>At]-Astatinated Radiopharmaceuticals and Applications in Targeted \hat{1}\pm-Particle Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 1-20.$	1.0	94
27	Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO — a selected review. Nuclear Medicine Review, 2011, 14, 90-95.	0.5	67
28	Feasibility of the radioastatination of a monoclonal antibody with astatineâ€211 purified by wet extraction. Journal of Labelled Compounds and Radiopharmaceuticals, 2008, 51, 379-383.	1.0	21